Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1947415-68-0
Molecular formula
C1575H2400N422O477S6
Molecular weight
35070 g/mol
Drug class
IgG-cleaving enzymeselective immunosuppressant
Mechanism of action
A cysteine protease derived from Streptococcus pyogenes that cleaves the heavy chains of human IgG, rapidly reducing donor-specific IgG antibodies and Fc-mediated effector activity.
Indications / reported uses
Desensitisation of highly sensitised adult kidney-transplant candidates with a positive crossmatch against an available deceased donor, under the authorised product indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Imlifidase PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Imlifidase Permitted Daily Exposure (PDE) report (the Imlifidase PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Imlifidase Occupational Exposure Limit (OEL) report (the Imlifidase OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.